Evaluation of a Series of beta-Secretase 1 Inhibitors Containing Novel Heteroaryl-Fused-Piperazine Amidine Warheads.
Oehlrich, D., Peschiulli, A., Tresadern, G., Van Gool, M., Vega, J.A., De Lucas, A.I., Alonso de Diego, S.A., Prokopcova, H., Austin, N., Van Brandt, S., Surkyn, M., De Cleyn, M., Vos, A., Rombouts, F.J.R., Macdonald, G., Moechars, D., Gijsen, H.J.M., Trabanco, A.A.(2019) ACS Med Chem Lett 10: 1159-1165
- PubMed: 31413800 
- DOI: https://doi.org/10.1021/acsmedchemlett.9b00181
- Primary Citation of Related Structures:  
6OD6 - PubMed Abstract: 
Despite several years of research, only a handful of β-secretase (BACE) 1 inhibitors have entered clinical trials as potential therapeutics against Alzheimer's disease. The intrinsic basic nature of low molecular weight, amidine-containing BACE 1 inhibitors makes them far from optimal as central nervous system drugs ...